MarketPulse

TERN-701

2 articles
BenzingaBenzinga··Vandana Singh

Merck Slashes Terns Pharma Offer to $53/Share After Trial Data Disappoints

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.
MRKNVSTERNacquisitionclinical trial data
BenzingaBenzinga··Globe Newswire

Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster CML Portfolio

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.
MRKTERNacquisitionM&A